Dexrazoxane Market Outlook:
Dexrazoxane Market size was valued at USD 887.7 million in 2025 and is projected to reach USD 1502 million by the end of 2035, rising at a CAGR of 5.4% during the forecast period, i.e., 2026 to 2035. In 2026, the industry size of dexrazoxane is estimated at USD 935.6 million.
The global dexrazoxane market is unfolding appreciable growth opportunities fueled by the growing demand for chemotherapy-based cardioprotection, coupled with anthracycline extravasation management. Besides, the NLM study in March 2022 reports that nearly 650,000 patients in the U.S. received anthracycline-based treatment measures, reflecting the demand for dexrazoxane. Additionally, the market expansion is significantly influenced by the synthesis of ingredients, that is, the supply chain is dominated by China and India, with high production. Similarly, formulations in GMP-certified facilities in the U.S., EU, and Japan are distributed through varied pharmaceutical networks, denoting a positive outlook for market upliftment.
At a trade and economic level, the producer price index for chemoprotectant agents has been fairly stable, reflecting established manufacturing, although vulnerable to variations in bulk API prices from overseas suppliers. Consumer prices, influenced to a large extent by reimbursement policy as opposed to direct purchase, are protected from immediate market volatility. The OEC report in 2023 depicts that the global export of pharmaceutical products has increased by 0.85% from 2022-2023. Further, the import-export dynamics are characterized by the export of bulk APIs from India and China to formulation and packaging plants in Western markets. The final drug product is then dispensed by specialty pharmaceutical wholesalers to hospital systems.
Dexrazoxane Market - Growth Drivers and Challenges
Growth Drivers
- Increased incidence of anthracycline-exposed cancers: The growing pool of patients is a basic driver of growth. Anthracyclines are still a cornerstone therapy for prevalent cancers such as breast cancer and lymphoma. In Germany, the incidence of breast cancer was more than 70,000 new cases, according to the NLM study in August 2024. This increased incidence has a direct relation on a higher population in need of cardioprotection. The manufacturers can use epidemiological information obtained from sources such as the CDC (CDC.gov) for purposes of identifying high-growth geographies and orientation of market entry based on the highest unmet need and volume of patients.
- Growing demand for cardioprotection: There is a surge in chemotherapy-induced cardiotoxicity and the need for cardioprotection that is driving growth in the dexrazoxane market. In this context, NIH states that dexrazoxane formulations are highly effective in the form of a cardioprotective agent, in cancer patients using anthracycline-based chemotherapy. Besides, in 2022 AHRQ study declared that this element lowered the cardiac hospitalization rates, conserving in the U.S. healthcare expenditure. Furthermore, in Europe, ESMO is recommending dexrazoxane for high-risk patients, thereby accelerating market growth.
- Focus on healthcare quality and cost-effectiveness: Payer focus on value-based care is a critical driver. NLM's March 2025 study points out that dexrazoxane significantly decreases the incidence of heart failure, particularly in sarcoma patients receiving high cumulative doses of doxorubicin. Heart failure incidence is as low as 1.1% in clinical trials with dexrazoxane compared with 5.4% without dexrazoxane. This information enables hospital systems to rationalize the drug's initial cost, fueling uptake as a best practice in quality oncology care and providing a compelling narrative for manufacturers during negotiations with payers.
Heart Failure and Cardiac Dysfunction Incidence in Contemporary Trials
|
Population |
Dexrazoxane Use (% use) |
Cumulative Doxorubicin Dose (mg/m²) |
Number of Patients |
Age Range (years) |
Heart Failure Incidence |
LVEF Decline (%) |
|
Leiomyosarcoma |
No |
360-450‡ |
149 |
30-86 |
5.4 |
NA |
|
Soft-Tissue Sarcoma |
Yes (38.6%) |
< 450 |
153 |
NA* |
2 |
16.2 (with dexrazoxane) 5.9 (without dexrazoxane) |
|
Soft-Tissue Sarcoma |
Yes (88.5%) |
450-599 |
159 |
NA |
3 |
9.9 (with dexrazoxane) 23.5 (without dexrazoxane) |
|
Soft-Tissue Sarcoma |
Yes (90%) |
≥ 600 |
89 |
NA |
1.1 |
12.5 (with dexrazoxane) 44.4 ( without dexrazoxane) |
|
Pediatric Osteosarcoma |
Yes (100%) |
450-600 |
242 |
3-30 |
0 |
2.1† |
Source: NLM March 2025
Challenges
- Stringent regulatory approvals: One of the major bottlenecks of dexrazoxane market is the strict regulations imposed by the governing bodies that delay the product’s market entry. Despite possessing higher efficacy, the product needs to undergo rigorous clinical trials for the exploration of its potential. Besides when compared to the U.S. Japan’s PMDA necessitates more than 6 months for approvals associated with oncology therapeutics. This adds higher expenses for the manufacturer, delaying product exposure across the healthcare industry.
- Budget restrictions in public health systems: Public health systems, particularly in developing countries, have limited oncology drug budgets. According to the WHO, cancer drug spending can take up a significant percentage of the national health budget (WHO.int). A supplier of dexrazoxane will be competing against the main chemotherapies themselves and therefore will be a lesser priority. This compels manufacturers to create tiered pricing models or get onto international aid programs in order to gain access in such markets.
Dexrazoxane Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.4% |
|
Base Year Market Size (2025) |
USD 887.7 million |
|
Forecast Year Market Size (2035) |
USD 1502 million |
|
Regional Scope |
|
Dexrazoxane Market Segmentation:
End user Segment Analysis
The hospital sub-segment is the largest end-user in the dexrazoxane market, which is expected to have the largest revenue share of 70% by 2035. This is mainly because of the drug's administration mode; as an intravenous infusion employed for the prevention of anthracycline-induced cardiotoxicity, it has to be administered in a controlled clinical environment under direct medical control during chemotherapy procedures. Hospitals and their related oncology departments have the required infrastructure, skilled staff, and equipment for safe administration and monitoring of patients.
Product Formulation Segment Analysis
The lyophilized powder form leads because of its better stability, long shelf-life, and simple reconstitution in hospital facilities, which is essential for an intravenous drug used in combination with chemotherapy. The June 2025 NLM report illustrates that the Essential Medicines lists supplies more than 70% of antibiotics as lyophilized sterile powders for injection. FDA regulatory guidelines prioritize the injectable formulation's stability, which has led to lyophilized powder being the preferred choice among manufacturers and clinicians alike, providing an assured consistency of efficacy and safety profiles (FDA.gov). Its logistical benefits are the rationale behind its market-leading revenue share.
Distribution Channel Segment Analysis
In the distribution channel segment, hospital pharmacies lead the segment as the dexrazoxane is usually used as intravenous drug administered in clinical setting under strict medical supervision during the sessions of chemotherapy. The NLM study in April 2022 depicts that overall pharmaceutical expenditure in hospital pharmacies increased by 7.7% in 2021 and totaled USD 576.9 billion. Moreover, it is not a retail pharmacy product. The Centers for Medicare & Medicaid Services policies that reimburse these drugs under hospital outpatient system, reinforce this channel. The requirement for controlled administration and monitoring ensures that distribution is centralized within hospital pharmacy networks.
Our in-depth analysis of the global market includes the following segments:
|
Segments |
Subsegments |
|
End user |
|
|
Product Formulation |
|
|
Application |
|
|
Distribution Channel |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Dexrazoxane Market - Regional Analysis
North America Market Insights
The North America dexrazoxane market is poised to capture the largest share of 40.5% during the forecast period, 2026-2035. The region benefits from the presence of emerging nations such as the U.S. and Canada, which contribute to the maximum revenue share in the region. U.S. dominates the North America market owing to the extensive utilization of chemotherapy treatments and insurance reimbursement policies. Besides, the CMS states that Medicare expenditure for this element in 2024, fueled by the coverage for pediatric oncology. The U.S. FDA’s 2023 label expansion for adults having a higher risk further increased the adoption of dexrazoxane, contributing to market progression in the region.
The U.S. dexrazoxane market is dominated by huge government expenditure and favorable reimbursement policy. The major trend is the increasing coverage of Medicare for cardioprotective agents due to population aging and long-term cancer care needs. As reported by the AACR Cancer Progress Report in 2025, the NIH’s National Cancer Institute (NCI) supports extensive research to focus on managing adverse effects of cancer treatments, with extramural grants contributing to overall NIH cancer research funding that surpassed USD 37.81 billion in FY 2023. There is also federal funding reflected, with the NIH having given priority to research on preventing chemotherapy side effects, solidifying demand. These together create a stable growth in the market, aiming to enhance patient outcomes in oncology care.
There is a huge opportunity for the market in Canada, driven by the increasing provincial healthcare investments. The market is anticipated to grow with government-backed funding and increasing instances of cancer cases. Besides, Ontario report in July 2023 states that Ontario for the Ministry of Health, provides 75% of the total funding for intravenous cancer drugs. This budget supports in adoption, accessibility, and clinical use as part of the broader oncology drug budget. Moreover, Health Canada mandated this element for pediatric anthracycline use, reflecting the higher efficacy.
Cancer Statistics in U.S. and Canada
|
Category |
U.S. (2025) |
Canada (2024) |
|
New Cancer Cases |
2,041,910 estimated new cases |
247,100 new cases |
|
Cancer Deaths |
618,120 estimated deaths |
88,100 deaths |
|
Men (Top 3 Cancers) |
Prostate, Lung, Colorectal 48% of diagnoses |
127,100 new cases (all cancers combined) |
|
Women (Top 3 Cancers) |
Breast, Lung, Colorectal → 51% of diagnoses |
120,000 new cases (all cancers combined) |
Source: National Cancer Institute May 2025, Canadian Cancer Society 2025
APAC Market Insights
Asia Pacific is expected to demonstrate the fastest growth in the market with its strong capacity in pharmaceuticals, including cancer therapeutics. The region is augmenting such growth due to the increasing burden of cancer, expanded medical access, and proactive government initiatives aiming to enhance management strategies. Besides, countries in the region are appreciably integrating cardioprotective therapies in cancer treatments, denoting an increased adoption. Hence, these factors will readily bolster the market positioning of Asia Pacific as a key leader in the market.
The market of dexrazoxane in India is growing at a very fast rate because of the high dedication of public and private healthcare centers to provide phenomenal cancer care. In this respect, the PRS Legislative Research report in 2025 has stated that during 2025-26, Rs 99,859 crore has been invested by the Ministry, which is an 11% rise compared to 2024-25 in the healthcare sector. This increased investment reflects more access to advanced oncology drugs such as dexrazoxane, bolstering cancer care infrastructure in India.
The China dexrazoxane market is experiencing stable growth, driven by the rising cancer burden and growing application of anthracycline-based chemotherapies that require cardioprotective measures. According to the NLM report in February 2022, the number of cancer cases in China in 2022 was 4,820,000. This persistent disease incidence underscores the need for supportive therapies such as dexrazoxane to avert chemotherapy-related adverse effects. Increased hospital infrastructure expansion, along with increased investment in oncology research, positions China as a leading emerging market for dexrazoxane in the Asian region.
Europe Market Insights
The market in Europe is influenced by high rates of cancer prevalence and treatment, strong healthcare infrastructure, and strict regulatory systems that provide drug safety and efficacy. Key growth drivers include the increasing adoption of anthracycline-based chemotherapy and a growing emphasis on cardioprotection to mitigate associated cardiac toxicity. Trends indicate a transition towards treatments, which include cardioprotective agents such as dexrazoxane that are driven by positive reimbursement policies and government programs.
The UK is set to have the largest revenue share in Europe by 2035, led by a strong healthcare policy environment and accelerated uptake of clinical guidelines. The National Institute for Health and Care Excellence (NICE) guideline recommends dexrazoxane for certain patient populations, providing uniform application in the NHS. Based on nhs.uk statistics, the Cancer Drugs Fund spending in 2023/2024 was about £247 million, covering early access to novel cancer drugs. Strong clinical research facilities in the UK, financed by Cancer Research UK, also enhance market penetration.
Germany is also leading the dexrazoxane market in Europe and is fueled by its rising population and comprehensive statutory health insurance system. The Federal Ministry of Health states that a continuus reimbursement expansion codes for support in oncological care. Further the high decentralized healthcare system in Germany allows a swift adoption in university hospitals and regional cancer centers. The major trend is rising the focus on outcomes on long term patient in reducing the chemotherapy related comorbidities which is prioritized by the German Cancer Research Center.
Cancer Drugs Fund Expenditure 2023-2024
|
Total CDF budget 2023/24 |
£340 million |
|
n/a |
Cumulative YTD Totals |
|
n/a |
Quarters 1 to 2 |
|
n/a |
Actual (£) |
|
Interim funding agreements |
£20.56 million |
|
Managed access agreements |
£226.51 million |
|
Total drug cost |
£247.07 million |
Source: NHS December 2024
Kry Dexrazoxane Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Companies involved in the market are witnessing intensifying competition between the global players in various regions. Leading firms such as Pfizer Inc. and Hikma Pharmaceuticals are gaining exceptional recognition with products such as Zinecard and Totect. Besides, companies in developing countries are enhancing manufacturing capabilities to meet the rising demand. Furthermore, firms are leveraging collaborations, regulatory support, and research investments to enhance their product portfolio. Hence, with these constant efforts from the players across all nations, the market will grow at the fastest rate.
Below is the list of some prominent players in the industry:
|
Company Name |
Origin |
Estimated 2025 Market Share (%) |
Industry Focus |
|
Pfizer Inc. |
U.S. |
25% |
Pharmaceutical giant; markets the branded version of Dexrazoxane (Totect/Zinecard) and is a key innovator and supplier, particularly in North America and Europe |
|
Teva Pharmaceutical Industries Ltd. |
Israel |
18% |
Leading global generics manufacturer; a major supplier of generic Dexrazoxane, focusing on cost-effective production and broad distribution networks |
|
Mylan N.V. (now part of Viatris) |
U.S. |
15% |
A major player in generic and specialty pharmaceuticals; produces and distributes generic Dexrazoxane, ensuring wide availability across multiple markets |
|
Hikma Pharmaceuticals PLC |
United Kingdom |
9% |
Multinational pharmaceutical company with a strong focus on generics; supplies Dexrazoxane in various regions, including the Middle East and North Africa (MENA) and the US |
|
Fresenius Kabi AG |
Germany |
7% |
Global healthcare company specializing in generic drugs and medical devices; supplies injectable Dexrazoxane, targeting hospital and clinical settings |
|
Sun Pharmaceutical Industries Ltd. |
India |
xx% |
India's largest pharmaceutical company; a significant manufacturer of generic Dexrazoxane, leveraging its extensive API and formulation capabilities for global supply |
|
Cipla Ltd. |
India |
xx% |
A leading Indian multinational known for its respiratory and oncology portfolio; produces and exports generic Dexrazoxane to emerging and developed markets |
|
Dr. Reddy's Laboratories Ltd. |
India |
xx% |
An integrated pharmaceutical company with a strong active pharmaceutical ingredient (API) and generics business; involved in the production of Dexrazoxane |
|
Sandoz International GmbH (Novartis division) |
Germany |
xx% |
A global leader in generics and biosimilars; markets generic Dexrazoxane, benefiting from the Novartis global infrastructure and regulatory expertise |
|
Accord Healthcare Inc. |
United Kingdom |
xx% |
One of Europe's fastest-growing pharmaceutical companies; focuses on generics and hospital products, including the supply of Dexrazoxane |
|
Gland Pharma Ltd. |
India |
xx% |
Specializes in injectable formulations; a contract development and manufacturing organization (CDMO) that may produce Dexrazoxane for other marketers |
|
Jiangsu Aosaikang Pharm Co., Ltd. |
China |
xx% |
Chinese pharmaceutical company with a growing focus on oncology drugs, including the manufacturing of Dexrazoxane for the domestic and select international markets |
|
Intas Pharmaceuticals Ltd. |
India |
xx% |
A prominent Indian pharmaceutical company with a strong presence in oncology; manufactures and markets generic Dexrazoxane |
|
Apotex Inc. |
Canada |
xx% |
A Canadian-based global generics company; produces and distributes a range of generic oncology drugs, including Dexrazoxane, primarily in North America |
|
Baxter International Inc. |
U.S. |
xx% |
A leading medtech and pharmaceutical company; supplies critical injectable drugs, with a potential role in the hospital supply chain for Dexrazoxane |
|
Nippon Kayaku Co., Ltd. |
Japan |
xx% |
A major Japanese chemical and pharmaceutical company with a significant focus on oncology; likely a key supplier and marketer of Dexrazoxane in the Japanese market |
|
Sawai Pharmaceutical Co., Ltd. |
Japan |
xx% |
A Japanese generic drug manufacturer with a strong domestic presence; produces generic versions of oncology drugs like Dexrazoxane for the Japanese healthcare system |
|
Kyowa Kirin Co., Ltd. |
Japan |
xx% |
A Japan-based multinational pharmaceutical company with a specialty in oncology and nephrology; may be involved in the marketing or development of Dexrazoxane in Japan |
|
Nichi-Iko Pharmaceutical Co., Ltd. |
Japan |
xx% |
A major Japanese generic drug manufacturer; a significant player in the domestic market for generic injectable drugs, including Dexrazoxane |
|
Takeda Pharmaceutical Company Limited |
Japan |
xx% |
Japan's largest pharmaceutical company; while focused on branded drugs, it may have a role in the distribution or legacy portfolio of oncology drugs like Dexrazoxane in Japan |
Below are the areas covered for each company in the market:
Recent Developments
- In May 2025, Reach Pharmaceuticals announced the TGA approval of DEXRAZOXANE-REACH for injection, which is used to reduce the incidence and severity of cardiomyopathy related to doxorubicin administration among women with breast cancer.
- In August 2023, CNX Therapeutics acquired nearly 4 medicines, such as Cardioxane (dexrazoxane), Totect (dexrazoxane), Savene (dexrazoxane), and Ethyol (amifostine), all of which help alleviate the side effects patients may experience when treated with any other cancer therapies.
- Report ID: 2614
- Published Date: Oct 03, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Dexrazoxane Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.
Afghanistan (+93)
Åland Islands (+358)
Albania (+355)
Algeria (+213)
American Samoa (+1684)
Andorra (+376)
Angola (+244)
Anguilla (+1264)
Antarctica (+672)
Antigua and Barbuda (+1268)
Argentina (+54)
Armenia (+374)
Aruba (+297)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas (+1242)
Bahrain (+973)
Bangladesh (+880)
Barbados (+1246)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bermuda (+1441)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Bouvet Island (+)
Brazil (+55)
British Indian Ocean Territory (+246)
British Virgin Islands (+1284)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Cayman Islands (+1345)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China (+86)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Colombia (+57)
Comoros (+269)
Cook Islands (+682)
Costa Rica (+506)
Croatia (+385)
Cuba (+53)
Curaçao (+599)
Cyprus (+357)
Czechia (+420)
Democratic Republic of the Congo (+243)
Denmark (+45)
Djibouti (+253)
Dominica (+1767)
Dominican Republic (+1809)
Timor-Leste (+670)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Falkland Islands (+500)
Faroe Islands (+298)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Gibraltar (+350)
Greece (+30)
Greenland (+299)
Grenada (+1473)
Guadeloupe (+590)
Guam (+1671)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hong Kong (+852)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Isle of Man (+44)
Israel (+972)
Italy (+39)
Jamaica (+1876)
Japan (+81)
Jersey (+44)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macao (+853)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mayotte (+262)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Montserrat (+1664)
Morocco (+212)
Mozambique (+258)
Myanmar (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Caledonia (+687)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Niue (+683)
Norfolk Island (+672)
North Korea (+850)
Northern Mariana Islands (+1670)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Palestine (+970)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Puerto Rico (+1787)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Barthélemy (+590)
Saint Helena, Ascension and Tristan da Cunha (+290)
Saint Kitts and Nevis (+1869)
Saint Lucia (+1758)
Saint Martin (French part) (+590)
Saint Pierre and Miquelon (+508)
Saint Vincent and the Grenadines (+1784)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Sint Maarten (Dutch part) (+1721)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
South Georgia and the South Sandwich Islands (+0)
South Korea (+82)
South Sudan (+211)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Svalbard and Jan Mayen (+47)
Eswatini (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Taiwan (+886)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Togo (+228)
Tokelau (+690)
Tonga (+676)
Trinidad and Tobago (+1868)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Turks and Caicos Islands (+1649)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+39)
Venezuela (Bolivarian Republic of) (+58)
Vietnam (+84)
Wallis and Futuna (+681)
Western Sahara (+212)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
